Beta Thalassaemia – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Beta Thalassaemia – Drugs In Development, 2023’, provides an overview of the Beta Thalassaemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Beta Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Beta Thalassaemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Beta Thalassaemia
- The report reviews pipeline therapeutics for Beta Thalassaemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Beta Thalassaemia therapeutics and enlists all their major and minor projects
- The report assesses Beta Thalassaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Beta Thalassaemia
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Beta Thalassaemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beta Thalassaemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abfero Pharmaceuticals IncAgios Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Ariya Bio
ASC Therapeutics Inc
Ascentage Pharma Group Inc
Beam Therapeutics Inc
Bellicum Pharmaceuticals Inc
Biomac Lifesciences Pvt Ltd
BRL Medicine Inc
Cell Source Inc
Centre for Stem Cell Research
Cetya Therapeutics Inc
CHA Biotech Co Ltd
CorrectSequence Therapeutics Co Ltd
CRISPR Therapeutics AG
CSL Ltd
Disc Medicine Inc
EdiGene Inc
Editas Medicine Inc
Garuda Therapeutics Inc
Genmedicn Biopharma Ltd
Guangzhou Reforgene Medicine Co Ltd
ImmuneCyte Inc
Invenux LLC
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Kanglin Biotech Hangzhou Co Ltd
Mabwell Therapeutics Inc
Merck & Co Inc
Merganser Biotech Inc
Mina Therapeutics Ltd
Monte Rosa Therapeutics Inc
Nanfang Hospital
Novartis AG
Novo Nordisk AS
Orchard Therapeutics Plc
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Rallybio Corp
Rare Partners Srl
Regenacy Pharmaceuticals LLC
San Rocco Therapeutics LLC
Sana Biotechnology Inc
Shanghai BDgene Therapeutics Co Ltd
Shanghai Vitalgen BioPharma Co Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Hemogen Gene Biotechnology Co Ltd
Silence Therapeutics Plc
Suzhou GenAssist Therapeutics Co Ltd
Syros Pharmaceuticals Inc
U.S. National Institutes of Health
University of Oxford
Vertex Pharmaceuticals Inc
Vifor Pharma Management Ltd
Weill Cornell Medical College